Register for free to listen to this article
Listen with Speechify
0:00
2:00
GUILDFORD, U.K.—MR Solutions, which introduced cryogen-free MRI scanners in 2012, is now offering a choice of two cryogen-free preclinical scanner ranges: the Flexiscan and Powerscan.
 
The Flexiscan range is available with multimodality accessories which can be mixed and matched according to research requirements. It is “a flexible MRI system,” according to the company, as it can incorporate integrated multimodality options such as PET or SPECT. The Flexiscan system reportedly requires no specialist knowledge and can be operated simply by running predefined settings. There is no need to materially alter the parameters of the machine.
 
The Powerscan range is available with adjustable magnetic field strengths ranging from 0.1T to 9.4T. The system allows physicists to alter the hardware, software, pulse sequences and algorithms to customize the capabilities of their preclinical imaging research.
 
“Our preclinical MRI product ranges now cover the best of both worlds: the Flexiscan, a simple to operate system which is ideally suited to most research laboratories, and a second product family, the Powerscan, for scientists who would like the ability to customize their system’s configuration,” said MR Solutions’ chief executive, Dr. David Taylor.
 
Both the Flexiscan and Powerscan ranges share the many advantages of being cryogen-free, “not the least of which is the lower price, as being cryogen-free eliminates the need for the large and cumbersome helium cooling system, the emergency venting system to cope with the helium turning to gas, or the expensive building alterations needed to accommodate it,” according to the company.
 
Another key advantage is that with a stray field of a few centimeters, the scanner can be placed near other scanners and sensitive equipment and does not require its own room. This speeds up transfer times between different scanning technologies.
 
Both systems can incorporate integrated PET and SPECT imaging solutions, allowing researchers to carry out independent imaging using the PET or SPECT modules, or sequential and simultaneous imaging. Software allows the co-registration of images to maximize the acquisition and quality of imaging data.

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue